Valeria Nicolini
YOU?
Author Swipe
View article: CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB
CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB Open
Background/Objectives: T cell bispecific antibodies (TCBs) result in the activation of T cell receptor signaling upon binding to tumor antigens providing signal 1 to T cells. To enhance and sustain their activity, a co-stimulatory signal 2…
View article: 863 A novel bispecific immuno-cytokine therapeutic: ‘switch on’ activity of a conditionally active PD1-IL2v delivering IL2v to PD1+ cells while reducing activity on PD1- cells
863 A novel bispecific immuno-cytokine therapeutic: ‘switch on’ activity of a conditionally active PD1-IL2v delivering IL2v to PD1+ cells while reducing activity on PD1- cells Open
View article: IMMU-26. Reinvigorating exhausted T cells in glioblastoma via PD1-IL2v immunocytokine therapy
IMMU-26. Reinvigorating exhausted T cells in glioblastoma via PD1-IL2v immunocytokine therapy Open
Glioblastoma (GBM) remains one of the most lethal primary brain tumors, characterized by profound immunosuppression and resistance to conventional immunotherapy. A hallmark of the GBM microenvironment is the prevalence of functionally exha…
View article: CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB
CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB Open
Background/Objectives: T cell bispecific antibodies (TCBs) result in the activation of T cell receptor signaling upon binding to tumor antigens providing signal 1 to T cells. To enhance and sustain their activity a co-stimulatory signal 2 …
View article: P08.21.A REINVIGORATING EXHAUSTED T CELLS IN GLIOBLASTOMA VIA PD1-IL2V IMMUNOCYTOKINE THERAPY
P08.21.A REINVIGORATING EXHAUSTED T CELLS IN GLIOBLASTOMA VIA PD1-IL2V IMMUNOCYTOKINE THERAPY Open
BACKGROUND Glioblastoma (GBM) remains one of the most lethal primary brain tumors, characterized by profound immunosuppression and resistance to conventional immunotherapy. A hallmark of the GBM microenvironment is the prevalence of functi…
View article: CEA-4-1BBL: Design and Optimization of a Novel CEACAM5-Targeted 4-1BB Ligand Antibody Fusion Protein to Provide Costimulation in Cis in Combination with T Cell Bispecific Antibodies
CEA-4-1BBL: Design and Optimization of a Novel CEACAM5-Targeted 4-1BB Ligand Antibody Fusion Protein to Provide Costimulation in Cis in Combination with T Cell Bispecific Antibodies Open
Background/Objectives: T cell bispecific antibodies (TCBs) activate T cells for the killing of tumor cells upon binding to tumor antigens resulting in the activation of T cell receptor signaling providing the so-called signal 1 to T cells.…
View article: Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma
Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma Open
T-cell engagers (TCEs) are transformative therapeutics in hematologic malignancies, including non-Hodgkin lymphoma. Initially approved for relapsed/refractory disease settings, TCEs are now explored in first-line and second-line settings, …
View article: Novel immunodominant neoepitope in a KPC mouse model of pancreatic cancer allowing identification of tumor-specific T cells
Novel immunodominant neoepitope in a KPC mouse model of pancreatic cancer allowing identification of tumor-specific T cells Open
The 4662 KPC model is one of the most widely used mouse models of pancreatic cancer. It represents an excluded immune phenotype and closely recapitulates the pathophysiology of pancreatic cancer in humans. We set out to identify the endoge…
View article: Supplementary Figure S3 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
Supplementary Figure S3 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade Open
(A-C) Relative frequency of stem-like (PD-1+TCF-1+TIM-3-) (A), transitory effector (PD-1+CX3CR1+TIM-3+) (B), and terminally differentiated (PD-1+CD101+TIM-3+) (C) Gp276+ and Gp33+ CD8 T cells in the spleen across treatment groups. Data are…
View article: Supplementary Figure S2 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
Supplementary Figure S2 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade Open
(A) Design of the acute LCMV infection experiment. (B) Number of total CD8+ T cells, and of activated (CD44high) and naïve (CD44low) CD8+ T cells in the spleen of acutely infected mice after treatment in the two groups. (C) Representative …
View article: Supplementary Figure S2 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
Supplementary Figure S2 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade Open
(A) Design of the acute LCMV infection experiment. (B) Number of total CD8+ T cells, and of activated (CD44high) and naïve (CD44low) CD8+ T cells in the spleen of acutely infected mice after treatment in the two groups. (C) Representative …
View article: Supplementary Figure S4 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
Supplementary Figure S4 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade Open
A) Number of total lymphocytes and of CD8+ T cells in the spleen of mice treated with either concomitant or sequential combination of CT and aPD-L1. (B) Representative FACS plots showing the frequency of stem-like (PD-1+TCF-1+TIM-3-), effe…
View article: Data from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
Data from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade Open
Purpose:Combination of chemotherapy with programmed cell death 1 (PD-1) blockade is a front-line treatment for lung cancer. However, it remains unknown whether and how chemotherapy affects the response of exhausted CD8 T cells to PD-1 bloc…
View article: Supplementary Figure S1 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
Supplementary Figure S1 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade Open
(A) Number of total lymphocytes, CD8 and CD4 T cells in the spleen across the treatment groups. (B-C) Frequency of PD-1+ and LCMV-specific CD8 T cells in the spleen and in the lung. Data are pooled from 2-3 experiments of 4-5 mice per grou…
View article: Supplementary Figure S1 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
Supplementary Figure S1 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade Open
(A) Number of total lymphocytes, CD8 and CD4 T cells in the spleen across the treatment groups. (B-C) Frequency of PD-1+ and LCMV-specific CD8 T cells in the spleen and in the lung. Data are pooled from 2-3 experiments of 4-5 mice per grou…
View article: Supplementary Figure S4 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
Supplementary Figure S4 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade Open
A) Number of total lymphocytes and of CD8+ T cells in the spleen of mice treated with either concomitant or sequential combination of CT and aPD-L1. (B) Representative FACS plots showing the frequency of stem-like (PD-1+TCF-1+TIM-3-), effe…
View article: Data from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
Data from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade Open
Purpose:Combination of chemotherapy with programmed cell death 1 (PD-1) blockade is a front-line treatment for lung cancer. However, it remains unknown whether and how chemotherapy affects the response of exhausted CD8 T cells to PD-1 bloc…
View article: Supplementary Figure S3 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
Supplementary Figure S3 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade Open
(A-C) Relative frequency of stem-like (PD-1+TCF-1+TIM-3-) (A), transitory effector (PD-1+CX3CR1+TIM-3+) (B), and terminally differentiated (PD-1+CD101+TIM-3+) (C) Gp276+ and Gp33+ CD8 T cells in the spleen across treatment groups. Data are…
View article: Supplementary Figure S2 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Supplementary Figure S2 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors Open
Supplementary Figure S2. Percent reduction in B cell numbers and B cell/T cell ratios in human CD20 transgenic mice treated with obinutuzumab or rituximab in A, Spleen and B, Lymph nodes. C, Reduction in splenic marginal zone B cells in hu…
View article: Supplementary Figure S5 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Supplementary Figure S5 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors Open
Supplementary Figure S5. The detailed effect of obinutuzumab pretreatment followed by CEA-IL2v on six timepoints from screening to Cycle 4 Day 5 of treatment. A, Peripheral blood natural killer cell count. B, Proliferating peripheral blood…
View article: Supplementary Figure S3 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Supplementary Figure S3 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors Open
Supplementary Figure S3. Efficacy of IL-2v alone and in combination with anti-PD-L1 in A, Wild-type C57BL/6 mice and B, B-cell deficient C57BL/6 mice. IL-2v, interleukin-2 variant; PD-L1, programmed death-ligand 1.
View article: Supplementary Table S1 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Supplementary Table S1 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors Open
Supplementary Table S1. Baseline demographic and clinical characteristics (safety population).
View article: Data from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Data from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors Open
Purpose:The immunocytokine cergutuzumab amunaleukin (CEA-IL2v) showed manageable safety and favorable pharmacodynamics in phase I/Ib trials in patients with advanced/metastatic carcinoembryonic antigen-positive (CEA+) solid tumors, but thi…
View article: Supplementary Table S2 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Supplementary Table S2 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors Open
Supplementary Table S2. Study representation of underserved communities.
View article: Data from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Data from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors Open
Purpose:The immunocytokine cergutuzumab amunaleukin (CEA-IL2v) showed manageable safety and favorable pharmacodynamics in phase I/Ib trials in patients with advanced/metastatic carcinoembryonic antigen-positive (CEA+) solid tumors, but thi…
View article: Supplementary Figure S5 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Supplementary Figure S5 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors Open
Supplementary Figure S5. The detailed effect of obinutuzumab pretreatment followed by CEA-IL2v on six timepoints from screening to Cycle 4 Day 5 of treatment. A, Peripheral blood natural killer cell count. B, Proliferating peripheral blood…
View article: Supplementary Figure S4 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Supplementary Figure S4 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors Open
Supplementary Figure S4. Full patient disposition for the Phase I/Ib substudies. A, CEA-IL2v monotherapy with or without obinutuzumab pretreatment. The red boxes indicate the data used to support the information included within the manuscr…
View article: Supplementary Figure S2 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Supplementary Figure S2 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors Open
Supplementary Figure S2. Percent reduction in B cell numbers and B cell/T cell ratios in human CD20 transgenic mice treated with obinutuzumab or rituximab in A, Spleen and B, Lymph nodes. C, Reduction in splenic marginal zone B cells in hu…
View article: Supplementary Figure S1 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Supplementary Figure S1 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors Open
Supplementary Figure S1. The effect of obinutuzumab pretreatment on A, De-novo vaccination with tetanus toxoid and B, Memory re-call to immune rechallenge with a measles/rubella vaccination in cynomolgus monkeys.
View article: Supplementary Table S2 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Supplementary Table S2 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors Open
Supplementary Table S2. Study representation of underserved communities.